FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161133634> ?p ?o ?g. }

• W2161133634 endingPage "S171" @default.
• W2161133634 startingPage "S159" @default.
• W2161133634 abstract "The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in human cancer since it contributes to a number of highly relevant processes in tumor development and progression, including cell proliferation, regulation of apoptotic cell death, angiogenesis and metastatic spread. Among a variety of approaches used to target EGFR signaling, EGFR blocking monoclonal antibodies and small molecular weight EGFR tyrosine kinase compounds have been successfully developed. The results of a large body of preclinical studies and clinical trials suggest that targeting the EGFR could represent a significant contribution to cancer therapy. Both types of agent exert a significant antiproliferative activity when used alone or in combination with conventional antitumor treatments, such as chemotherapy or radiation therapy. Although the advanced clinical development of EGFR blocking drugs demonstrates their efficacy in some human metastatic diseases, such as lung, head and neck and colorectal cancers, the issue of constitutive resistance in a large number of patients and the development of acquired resistance in the responders remains an unexplored subject of investigation. Recent evidence suggests the role of specific activating mutations within the tyrosine kinase domain of EGFR to explain the dramatic responses to small molecule tyrosine kinase inhibitors in a subgroup of lung cancer patients. However, the intrinsic molecular mechanisms of resistance to these drugs are still unclear. This review will focus on the preclinical findings on therapeutic resistance to EGFR targeting agents." @default.
• W2161133634 created "2016-06-24" @default.
• W2161133634 creator A5020655022 @default.
• W2161133634 creator A5040413764 @default.
• W2161133634 creator A5050215401 @default.
• W2161133634 creator A5056034569 @default.
• W2161133634 date "2005-07-01" @default.
• W2161133634 modified "2023-10-16" @default.
• W2161133634 title "Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy" @default.
• W2161133634 cites W1544851750 @default.
• W2161133634 cites W1560121420 @default.
• W2161133634 cites W1594020010 @default.
• W2161133634 cites W1599518523 @default.
• W2161133634 cites W1606090394 @default.
• W2161133634 cites W1653571790 @default.
• W2161133634 cites W1777564233 @default.
• W2161133634 cites W1797430954 @default.
• W2161133634 cites W1811421440 @default.
• W2161133634 cites W1813102148 @default.
• W2161133634 cites W1848898216 @default.
• W2161133634 cites W1933350662 @default.
• W2161133634 cites W1963981090 @default.
• W2161133634 cites W1967304777 @default.
• W2161133634 cites W1970285990 @default.
• W2161133634 cites W1973186217 @default.
• W2161133634 cites W1978916359 @default.
• W2161133634 cites W1979909416 @default.
• W2161133634 cites W2000079492 @default.
• W2161133634 cites W2000923441 @default.
• W2161133634 cites W2001453148 @default.
• W2161133634 cites W2005204942 @default.
• W2161133634 cites W2005631145 @default.
• W2161133634 cites W2013878898 @default.
• W2161133634 cites W2014383618 @default.
• W2161133634 cites W2016710415 @default.
• W2161133634 cites W2019895529 @default.
• W2161133634 cites W2020636054 @default.
• W2161133634 cites W2024220711 @default.
• W2161133634 cites W2026389791 @default.
• W2161133634 cites W2026727845 @default.
• W2161133634 cites W2027524654 @default.
• W2161133634 cites W2033595975 @default.
• W2161133634 cites W2037455744 @default.
• W2161133634 cites W2042280647 @default.
• W2161133634 cites W2043220342 @default.
• W2161133634 cites W2043696829 @default.
• W2161133634 cites W2051120695 @default.
• W2161133634 cites W2057935373 @default.
• W2161133634 cites W2058783998 @default.
• W2161133634 cites W2059411043 @default.
• W2161133634 cites W2064047613 @default.
• W2161133634 cites W2069153761 @default.
• W2161133634 cites W2071551577 @default.
• W2161133634 cites W2077648006 @default.
• W2161133634 cites W2081070994 @default.
• W2161133634 cites W2084186083 @default.
• W2161133634 cites W2090390034 @default.
• W2161133634 cites W2091465371 @default.
• W2161133634 cites W2098544382 @default.
• W2161133634 cites W2112810120 @default.
• W2161133634 cites W2113280225 @default.
• W2161133634 cites W2114986305 @default.
• W2161133634 cites W2117503386 @default.
• W2161133634 cites W2118146357 @default.
• W2161133634 cites W2121155023 @default.
• W2161133634 cites W2121566802 @default.
• W2161133634 cites W2122522737 @default.
• W2161133634 cites W2128402413 @default.
• W2161133634 cites W2128412799 @default.
• W2161133634 cites W2130461015 @default.
• W2161133634 cites W2133051701 @default.
• W2161133634 cites W2133138712 @default.
• W2161133634 cites W2134610254 @default.
• W2161133634 cites W2139236349 @default.
• W2161133634 cites W2140513230 @default.
• W2161133634 cites W2143039477 @default.
• W2161133634 cites W2143536404 @default.
• W2161133634 cites W2145854263 @default.
• W2161133634 cites W2147703884 @default.
• W2161133634 cites W2151808807 @default.
• W2161133634 cites W2153534791 @default.
• W2161133634 cites W2155977433 @default.
• W2161133634 cites W2157191533 @default.
• W2161133634 cites W2160511594 @default.
• W2161133634 cites W2161821474 @default.
• W2161133634 cites W2163252214 @default.
• W2161133634 cites W2188010225 @default.
• W2161133634 cites W2317057093 @default.
• W2161133634 cites W2334507849 @default.
• W2161133634 cites W2388163742 @default.
• W2161133634 cites W230333478 @default.
• W2161133634 doi "https://doi.org/10.1677/erc.1.00999" @default.
• W2161133634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16113092" @default.
• W2161133634 hasPublicationYear "2005" @default.
• W2161133634 type Work @default.
• W2161133634 sameAs 2161133634 @default.
• W2161133634 citedByCount "84" @default.
• W2161133634 countsByYear W21611336342012 @default.

• next